Loading...
Loading...
MRNA| Name | Value |
|---|---|
| Revenues | 241.0M |
| Cost of Revenue | 156.0M |
| Gross Profit | 85.0M |
| Operating Expense | 1,448.0M |
| Operating I/L | -1,363.0M |
| Other Income/Expense | 84.0M |
| Interest Income | 111.0M |
| Pretax | -1,279.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -1,279.0M |
Moderna, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of messenger RNA therapeutics and vaccines for various diseases. Its product portfolio includes respiratory vaccines for COVID-19, flu, and other viruses, as well as latent and public health vaccines. Additionally, the company offers systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology products, and localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. Moderna generates revenue through the sale of its vaccines and therapeutics, as well as through strategic alliances and collaboration agreements with pharmaceutical and research organizations.
